Last reviewed · How we verify
Metronidazole gel versus placebo gel
Metronidazole gel versus placebo gel is a Nitroimidazole antibiotic Small molecule drug developed by Johns Hopkins Bloomberg School of Public Health. It is currently in Phase 3 development for Bacterial vaginosis (topical gel formulation), Rosacea (topical gel formulation), Anaerobic bacterial infections (systemic formulation).
Metronidazole is a nitroimidazole antibiotic that disrupts bacterial DNA by generating reactive oxygen species, killing anaerobic bacteria and certain protozoa.
Metronidazole is a nitroimidazole antibiotic that disrupts bacterial DNA by generating reactive oxygen species, killing anaerobic bacteria and certain protozoa. Used for Bacterial vaginosis (topical gel formulation), Rosacea (topical gel formulation), Anaerobic bacterial infections (systemic formulation).
At a glance
| Generic name | Metronidazole gel versus placebo gel |
|---|---|
| Sponsor | Johns Hopkins Bloomberg School of Public Health |
| Drug class | Nitroimidazole antibiotic |
| Target | Bacterial DNA (via reactive oxygen species generation) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Dermatology |
| Phase | Phase 3 |
Mechanism of action
Metronidazole is reduced by anaerobic organisms to form reactive intermediates that damage bacterial DNA and proteins, leading to cell death. It is effective against anaerobic bacteria and parasites but has no activity against aerobic organisms. The gel formulation allows topical delivery for localized infections or conditions.
Approved indications
- Bacterial vaginosis (topical gel formulation)
- Rosacea (topical gel formulation)
- Anaerobic bacterial infections (systemic formulation)
Common side effects
- Vaginal irritation or burning
- Metallic taste (systemic)
- Nausea (systemic)
- Local application site reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metronidazole gel versus placebo gel CI brief — competitive landscape report
- Metronidazole gel versus placebo gel updates RSS · CI watch RSS
- Johns Hopkins Bloomberg School of Public Health portfolio CI
Frequently asked questions about Metronidazole gel versus placebo gel
What is Metronidazole gel versus placebo gel?
How does Metronidazole gel versus placebo gel work?
What is Metronidazole gel versus placebo gel used for?
Who makes Metronidazole gel versus placebo gel?
What drug class is Metronidazole gel versus placebo gel in?
What development phase is Metronidazole gel versus placebo gel in?
What are the side effects of Metronidazole gel versus placebo gel?
What does Metronidazole gel versus placebo gel target?
Related
- Drug class: All Nitroimidazole antibiotic drugs
- Target: All drugs targeting Bacterial DNA (via reactive oxygen species generation)
- Manufacturer: Johns Hopkins Bloomberg School of Public Health — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Dermatology
- Indication: Drugs for Bacterial vaginosis (topical gel formulation)
- Indication: Drugs for Rosacea (topical gel formulation)
- Indication: Drugs for Anaerobic bacterial infections (systemic formulation)
- Compare: Metronidazole gel versus placebo gel vs similar drugs
- Pricing: Metronidazole gel versus placebo gel cost, discount & access